Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2. Qiu X, Tarantino P, Li R, et al. Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2. ESMO open. 2025;10(2):104111. doi:10.1016/j.esmoop.2024.104111 Read more